![]() The table below outlines the results of the 5 patients. All patients had suspicion or confirmation of NET’s by clinical presentation and by other diagnostic imaging modalities. Results: Patients age ranged from 5 to 17 years old with a mean of 12 4 females and 1 male. A low-dose non-contrast CT was performed for anatomical localization and attenuation correction. Imaging was obtained from skull base to proximal thigh for 5 minutes per bed position using 2D acquisition. ![]() Imaging commenced approximately 60 minutes post administration. Patients were well hydrated prior to administration and asked to void frequently, and to continue this for several hours after the exam. Patients were injected with 0.054 mCi/kg (2 MBq/kq) Gallium-68 NETSPOT, maximum dose of 5.4 mCi (200 MBq) mCi, minimum dose 2 mCi (74MBq). Patients were instructed to pause somatostatin / octreotide therapy. Pediatric patient preparation involved no dietary restrictions. Methods: A total of 5 pediatric patients were imaged. The objective of this abstract presentation is to outline our experience with imaging pediatric patients suspected or confirmed of having a somatostatin receptor positive neuroendocrine tumor (NET). Because of the rarity of NET’s in children and adolescence the amount of experience in imaging such patients are extremely limited. NET’s are extremely rare in children and adolescence, with an incidence rate of 2.8 per million under the age of 30. Gallium- 68 dotatate, a positron-emitting analogue of somatostatin that binds to somatostatin receptors. NETs are rare noncancerous or cancerous tumors that develop in the hormone-producing cells of the body’s neuroendocrine system that have receptors for somatostatin. NETSPOT Full U.S.Objectives: Gallium-68 Dotatate (NETSPOT) is a PET radiotracer for use in the localization of somatostatin receptor positive neuroendocrine tumors (NETs). Please contact us at 95 for further details. This product has been designated as an orphan drug by the EMA and the FDA. NETSPOT™ is a novel patented kit developed by AAA for the preparation of gallium Ga 68 dotatate for injection, for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients using Positron Emission Tomography (“PET“). NETSPOT™ is a significant improvement over existing diagnostic tools and will enable us to more accurately stage and better manage patients. In a clinical study, NETSPOT™ demonstrated the ability to change management decisions regarding patients in 71% of cases previously imaged with Octreoscan. Saving just one patient from futile surgery can improve the treatment experience overall and significantly reduce the cost of care by reducing repetitive, often frustrating, and limitless diagnostics. ![]() NETSPOT™ offers superior sensitivity and accuracy compared to previously available diagnostics for NET patients. Gallium PET/CT also allows for calculation of standardized uptake value, has less whole body radiation, and is performed in less time versus Octreoscan. Gallium PET/CT is more accurate for staging and superior to Octreoscan SPECT in the detection of overall number of lesions in the body as well as organs and bones. Use of NETSPOT changed patient treatment and management in 71% of patients due to greater specificity compared to Octreoscan. It is a form of octreotide, which binds to a receptor on many NETs called the Somatostatin Receptor. NETSPOT, the new tracer for Gallium 68-Dotatate scan, is the next generation of OCTREOSCAN. PET Imaging Institute of South Florida is proud to offer newly available NETSPOT (Gallium 68-Dotatate) scan: A novel PET/CT tracer for the detection of Neuro Endocrine Tumors (NETs) ![]()
0 Comments
Leave a Reply. |